ClinicalTrials.gg

Program

mezagitamab

Also written as “Mezagitamab” and “TAK-079”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Multiple Myeloma · Kidney Diseases · Glomerulonephritis · Lupus Erythematosus, Systemic, led by Takeda.

Furthest: phase 3, since Dec 5, 202411 company-led studies, 4 open or runningNext primary completion: Mar 16, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda114 open or runningphase 3since Dec 5, 2024Aug 14, 2014Mar 16, 2028phase 3 · NCT06722235

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 14, 2014First study: phase 1 study in Autoimmune DiseasesFirst studyNCT02219256 · 74 enrolled · United Kingdom
  2. Feb 14, 2018Phase 2 study in RecurrenceNCT03439280 · 50 enrolled · United States
  3. Oct 18, 2018Phase 1 study in Lupus Erythematosus, SystemicNCT03724916 · 23 enrolled · United States
  4. Jun 11, 2019Phase 1 study in Multiple MyelomaNCT03984097 · 50 enrolled · United States
  5. Nov 8, 2019Phase 2 study in Myasthenia GravisNCT04159805 · 36 enrolled · United States, Canada, Italy and more
  6. Feb 19, 2020Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT04278924 · 41 enrolled · United States, Bulgaria, China and more
  7. Dec 14, 2021Phase 1 study in Kidney DiseasesNCT05174221 · 17 enrolled · United States, Australia, China and more
  8. Dec 5, 2024Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06722235 · 171 planned · United States, Australia, Bulgaria and more
  9. Apr 25, 20252 phase 3 studiesNCT06948318, NCT06963827
  10. May 22, 2026Phase 2 study in Antibody-Mediated Rejection (AMR)NCT07613359 · 36 planned · United States, China, France and more

Ahead

  1. Mar 16, 2028Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06722235
  2. Sep 7, 2028Primary completion: phase 3 study in Kidney DiseasesNCT06963827
  3. Jan 15, 2029Primary completion: phase 2 study in Antibody-Mediated Rejection (AMR)NCT07613359
  4. Jul 29, 2029Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06948318

TargetBeta

CD38 →read by rule
“A human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 binding agent”ChEMBL 37, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
felzartamabruleBiogenphase 315
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07613359Antibody-Mediated Rejection (AMR) · United States, China, France and more2RecruitingJan 15, 202936
NCT06963827Kidney Diseases · United States, Argentina, Australia and more3RecruitingSep 7, 2028347
NCT06948318Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Bulgaria and more3RecruitingJul 29, 2029150
NCT06722235Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Bulgaria and more3RecruitingMar 16, 2028171
NCT05174221Kidney Diseases · United States, Australia, China and more1CompletedDec 15, 202517
NCT04278924Purpura, Thrombocytopenic, Idiopathic · United States, Bulgaria, China and more2CompletedApr 29, 202441
NCT04159805Myasthenia Gravis · United States, Canada, Italy and more2CompletedJul 12, 202236
NCT03984097Multiple Myeloma · United States1CompletedMar 25, 202650
NCT03724916Lupus Erythematosus, Systemic · United States1CompletedNov 4, 202123
NCT03439280Recurrence · United States2CompletedJan 28, 202250
NCT02219256Autoimmune Diseases · United Kingdom1CompletedApr 201674

How it is read

Names in the registry

  • “Mezagitamab”, 6 entries
  • “TAK-079”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.